Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Andrea Harzstark, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01616186
First received: June 4, 2012
Last updated: April 4, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: April 2016
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)